Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

Diabetes, Obesity and Metabolism

Volumn 20, Issue 5, 2018, Pages 1111-1120

  Pratley, Richard E ^a   Eldor, Roy ^b   Raji, Annaswamy ^b   Golm, Gregory ^b   Huyck, Susan B ^b   Qiu, Yanping ^c   Sunga, Sheila ^b   Johnson, Jeremy ^b   Terra, Steven G ^d   Mancuso, James P ^d   Engel, Samuel S ^b   Lauring, Brett ^b  

^a FLORIDA HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MSD China   (China)

^d PFIZER INC   (United States)

Author keywords

clinical trial; DPP IV inhibitor; glycaemic control; phase III study; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

ERTUGLIFLOZIN; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SITAGLIPTIN; TRIACYLGLYCEROL; 5-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-1-HYDROXYMETHYL-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FUSED HETEROCYCLIC RINGS; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BALANOPOSTHITIS; BODY WEIGHT; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FACTORIAL DESIGN; FEMALE; FUNGAL GENITAL INFECTION; GENITAL CANDIDIASIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HAND FRACTURE; HEMATOCRIT; HUMAN; HYPOGLYCEMIA; HYPOVOLEMIA; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; ADMINISTRATION AND DOSAGE; AGED; BLOOD; BODY MASS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DOSE RESPONSE; DRUG RESISTANCE; FOLLOW UP; HYPERGLYCEMIA; OBESITY;

AGED; BODY MASS INDEX; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; OVERWEIGHT; SITAGLIPTIN PHOSPHATE; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85044247632     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13194     Document Type: Article

References (28)

1. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40:S64-S74.
2. Scheen AJ. Pharmacokinetic characteristics and clinical efficacy of an SGLT2 inhibitor plus DPP-4 inhibitor combination therapy in type 2 diabetes. Clin Pharmacokinet. 2017;56:703-718.
3. Kalgutkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011;39:1609-1619.
4. Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17:591-598.
5. Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19:721-728.
6. Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20:520–529.
7. Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20:530–540.
8. Merck & Co I. JANUVIA (Sitagliptin) prescribing information. Available at https://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf Accessed November 16, 2017.
9. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564-2571.
10. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24:537-550.
11. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733-745.
12. Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther. 2013;4:119-145.
13. American Diabetes Association. Executive summary: standards of medical care in diabetes--2012. Diabetes Care. 2012;35(suppl 1):S4-S10.
14. Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya Ser B. 2000;62:134-148.
15. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
16. Toffolo G, Breda E, Cavaghan MK, Ehrmann DA, Polonsky KS, Cobelli C. Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab. 2001;280:E2-10.
17. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-1380.
18. Amin NB, Wang X, Mitchell JR, Lee DS, Nucci G, Rusnak JM. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17:805-808.
19. Polidori D, Capuano G, Qiu R. Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy. Diabetes Obes Metab. 2016;18:348-354.
20. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384-393.
21. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376-383.
22. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515-531.
23. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study G. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979-1987.
24. Desai M, Yavin Y, Balis D, et al. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2017;19:897-900.
25. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-334.
26. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
27. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232-242.
28. Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65:2032-2038.